Anti-HBs Ag

The Anti-HBs test indicates the presence of protective antibodies developed against hepatitis B. These antibodies form after vaccination or following a past infection. The test holds clinical significance in evaluating immunity levels and confirming protection.

Anti-HBs level measurement determines the adequacy of antibody concentration and evaluates the sustainability of immunity. Results help identify vaccination needs, especially in high-risk groups, and support individual protection strategies.

Anti-HBs immunity screening is routinely performed in healthcare workers and people with high exposure risk. This screening determines whether the protective response is sufficient in potential HBV exposure and contributes to booster dose planning when necessary.

Anti-HBs follow-up analysis strengthens hepatitis B control programs at the community level. The prevalence of antibody positivity evaluates vaccination success, enables updates to public health policies, and supports long-term protection strategies.

What Is Anti-HBs Ag?

Anti-HBs is an antibody that indicates immunity developed against the Hepatitis B virus (HBV). It becomes positive after vaccination or after recovering from the disease. The presence of this antibody shows that the person is protected against Hepatitis B. The term “Ag” is often confused with the surface antigen (HBsAg); HBsAg indicates the presence of the virus, while Anti-HBs indicates immunity.

What does it mean if the HBsAg test is positive?

HBsAg (Hepatitis B surface antigen) is a protein found on the outer surface of the virus. A “positive” HBsAg result in a blood test indicates that Hepatitis B virus is actively present in the person’s body, meaning they are currently “infected.”

This also means that the person can transmit the virus to others through blood and other bodily fluids. If HBsAg positivity persists for more than six months, this condition is referred to as “chronic Hepatitis B infection” or, commonly, “carrier state.” In IVF treatment, HBsAg positivity is one of the most important findings requiring special precautions for both the mother and the father.

What is the Anti-HBs antibody and how does it show immunity?

Anti-HBs (Hepatitis B surface antibody) is the opposite of HBsAg. It is a protective “shield” produced by the body’s immune system against the virus (antigen). A “positive” Anti-HBs result in a blood test is excellent news, indicating that the person is immune to the Hepatitis B virus.

There are two ways to gain this protection:

• Hepatitis B vaccination
• Recovering naturally after a past infection

An Anti-HBs level above 10 mIU/mL is generally considered “full protection” and indicates that the person will no longer be affected by the Hepatitis B virus. In IVF, if one partner is Anti-HBs positive, all risks for that person are eliminated.

What about the Anti-HBc test, and why is it requested together with HBsAg and Anti-HBs?

This test is the “detective” that provides the most information in the panel. Anti-HBc (Hepatitis B core antibody) is an antibody produced against the virus’s core structure, not its outer shell (HBsAg).

Its key role is this: It allows us to distinguish vaccination from natural infection. Hepatitis B vaccines contain only the surface protein (HBsAg) of the virus, not its core.

Simply put:

• Vaccinated individuals (only exposed to the virus’s outer shell): Anti-HBc NEGATIVE.
• Individuals who had the infection (exposed to the whole virus including the core): Anti-HBc POSITIVE.

Therefore, Anti-HBc testing is essential to understand whether Anti-HBs positivity is due to vaccination or past infection.

How are all these Hepatitis B test panel results interpreted?

The combination of the three tests (HBsAg, Anti-HBs, Anti-HBc) clearly reveals your status. The most common scenarios and their meanings for IVF are:

• Scenario 1: Susceptible (Unprotected)

HBsAg: Negative

Anti-HBs: Negative

Anti-HBc: Negative

Meaning: The person has never encountered the virus and has not been vaccinated. Completely open to infection.

What to do: Hepatitis B vaccination should be administered immediately.

• Scenario 2: Immune Through Vaccination

HBsAg: Negative

Anti-HBs: Positive

Anti-HBc: Negative

Meaning: The person is successfully vaccinated and protected.

What to do: Excellent result. No barrier for IVF treatment.

• Scenario 3: Naturally Immune (Recovered)

HBsAg: Negative

Anti-HBs: Positive

Anti-HBc: Positive

Meaning: The person had the infection in the past, recovered, and gained permanent immunity.

What to do: No barrier for treatment.

• Scenario 4: Chronic Infection (Carrier)

HBsAg: Positive

Anti-HBs: Negative

Anti-HBc: Positive

Meaning: The virus has been in the body for more than 6 months. The person is a chronic Hepatitis B carrier.

What to do: Detailed evaluation before IVF (HBV DNA, liver enzymes) and joint follow-up with an infectious diseases/hepatology specialist is necessary.

• Scenario 5: Confusing (Isolated Anti-HBc Positivity)

HBsAg: Negative

Anti-HBs: Negative

Anti-HBc: Positive

Meaning: This is the most complex scenario. It may indicate false positivity, a very old past infection (Anti-HBs lost over time), or “occult” infection.

What to do: HBV DNA (viral load) test is required to check whether the virus is present in the blood. Actions depend on the result.

Why are HBsAg and Anti-HBs mandatory before IVF treatment?

Requesting these tests from all couples before IVF is not optional; it is an international medical requirement to protect both you and your future child.

There are three main purposes of this screening:

• Preventing transmission between partners (horizontal transmission).
• Preventing transmission from mother to baby (vertical transmission).
• Eliminating the risk of contamination between laboratory samples.

What if one partner is HBsAg positive and the other Anti-HBs negative (serodiscordant couple)?

This is common in IVF practice and is called a “serodiscordant couple” (one positive, the other negative/unprotected). The solution is clear and effective.

The first and most important step is immediate vaccination of the negative (susceptible) partner.

The partner must complete the 3-dose vaccination schedule and then have Anti-HBs levels checked to confirm immunity (>10 mIU/mL). This may delay treatment slightly, but it is absolutely necessary for safety.

Until immunity is confirmed, the couple should use barrier contraception (condom) to prevent horizontal transmission. Once immunity develops, this risk disappears and treatment can begin safely.

Does HBsAg positivity in the male partner affect sperm quality or Hepatitis B transmission risk?

This has two aspects. First is sperm quality. Yes, scientific studies show that HBsAg-positive men may have reduced sperm quality due to chronic inflammation caused by the virus.

Most common effects include:

• Decreased sperm motility (asthenozoospermia)
• Reduced sperm viability (necrozoospermia)
• Abnormal sperm morphology (teratozoospermia)

Fortunately, IVF technology overcomes this. In intracytoplasmic sperm injection (ICSI), the embryologist selects the healthiest sperm and injects it directly into the egg, eliminating negative effects of the virus on movement or count.

Second is the transmission risk. Transmission from male to female is prevented entirely by vaccinating the female partner.

Is “sperm washing” necessary in HBsAg-positive men?

Common and important question. Unlike HIV, special “sperm washing” is not required for Hepatitis B—as long as the female partner is fully protected (Anti-HBs positive >10).

The strategy is not to “clean the sperm,” but to “protect the partner.” If the partner is protected, this extra procedure is unnecessary.

However, this does not mean sperm undergo no processing. Standard semen preparation methods used in IVF (gradient or swim-up) select the healthiest sperm and separate them from seminal fluid where the virus may be present.

How does HBsAg positivity in the female partner affect IVF success?

This scenario requires careful management. Although studies vary, the general consensus is: IVF success (pregnancy and live birth rates) is usually not affected in women who are inactive carriers (low viral load and normal liver enzymes).

However, if the virus is actively replicating (high viral load and high liver enzymes), inflammation may impact egg quality or reserve. Therefore, every HBsAg-positive woman must be evaluated by an infectious diseases or hepatology specialist before IVF and receive “clearance.”

Why is the viral load (HBV DNA) test so crucial in HBsAg-positive women?

If the woman is HBsAg positive, the key test is HBV DNA, the “viral load.” This test counts the number of viruses per milliliter of blood. This number directly determines the risk of mother-to-baby transmission.

There is a medical “threshold value”: 200,000 IU/mL.

If the viral load is below this level, standard newborn protection at birth (vaccine + HBIG) is usually sufficient.

If above this level, the virus concentration is so high that standard protection may not be enough. This is when additional precautions are needed.

How are antiviral treatment and delivery planned in HBsAg-positive pregnant women?

If HBV DNA exceeds 200,000 IU/mL, safe antiviral medications used during pregnancy are initiated.

The goal is not to treat the mother’s liver disease but to lower the viral load below the dangerous threshold to protect the baby at birth.

These medications typically start in the third trimester (28–32 weeks) and continue for a short period after birth. Planning is coordinated between the IVF specialist, obstetrician, and hepatologist.

Delivery and breastfeeding guidelines are clear:

Delivery Method: Hepatitis B does not require cesarean delivery. Mode of delivery depends on routine obstetric reasons.

Breastfeeding: Breastfeeding is COMPLETELY SAFE as long as the newborn receives the first protection (vaccine + HBIG) at birth.

What steps are taken to protect a baby born to an HBsAg-positive mother?

This is a relay race. Once pregnancy begins, the IVF team informs the obstetrician, and the obstetrician informs the neonatologist about the mother’s HBsAg-positive status.

The “gold standard” protocol is applied, and its success depends on timing.

Within the first 12 hours of birth (ideally in the delivery room), the baby receives two injections:

Hepatitis B Vaccine (1st Dose): Stimulates the baby’s own immune system for long-term protection.

Hepatitis B Immunoglobulin (HBIG): These are “ready-made soldiers” (passive immunity). They immediately neutralize any virus that may have passed from the mother.

This combined approach—and antiviral therapy during pregnancy if needed—prevents mother-to-child transmission with over 95% success.

How is the baby followed after Hepatitis B vaccine and HBIG?

The job does not end in the delivery room. The baby continues the normal vaccination schedule (typically at 1 and 6 months).

After completing the series, when the baby is 9–12 months old, a “protection check” blood test is done. Only two markers are assessed: HBsAg and Anti-HBs.

These results show one of three possibilities:

• HBsAg (-) / Anti-HBs (+): Success! The baby is not infected and has developed immunity by producing Anti-HBs.
• HBsAg (-) / Anti-HBs (-): Not infected but no response. The baby is still unprotected and must repeat the 3-dose series.
• HBsAg (+) / Anti-HBs (-): Failure. Very rarely, infection has occurred. The baby must be followed by a pediatric hepatologist.

How are embryos from HBsAg-positive patients kept safe in the laboratory?

One of the biggest concerns in IVF patients is laboratory safety: “Can our samples contaminate others or vice versa?”

Modern, accredited IVF laboratories apply strict safety protocols. Even though theoretical risk is near zero, the goal is absolute zero.

Key safety measures include:

• Separate Work Areas: Eggs, sperm, and embryos belonging to HBsAg-positive (or other blood-borne virus–positive) patients are processed in physically separate biosafety cabinets.
• Separate Freezing Tanks: The most critical rule. Frozen sperm, eggs, or embryos of HBsAg-positive patients are *never* stored in tanks with other patients’ samples. Dedicated “infectious” or “quarantine” liquid nitrogen tanks are used.
• High-Security Carriers: Special sealed, hermetically closed carriers (such as cryotops or straws) are used for cryopreservation.

Frequently Asked Questions